Shares of XtalPi Holdings Ltd (HKG:2228) surged 5.77% in pre-market trading on Tuesday, following the company's announcement of positive financial expectations for the first half of 2025. The pharmaceutical research firm's stock price jump reflects investor optimism about its projected return to profitability.

According to a Hong Kong bourse filing on Tuesday, XtalPi expects to post a net profit of at least 50 million yuan for the six months ended June 30, 2025. This marks a significant turnaround from the 1.24 billion yuan loss reported in the same period last year. The company also anticipates a substantial increase in revenue, projecting at least 500 million yuan, which represents a year-over-year growth of at least 387%.

XtalPi further stated that it expects an adjusted net profit of at least 120 million yuan for the first half of 2025. This positive outlook has sparked investor interest, contributing to the stock's pre-market rally. The company is scheduled to release its detailed financial results by the end of August, which may provide more insight into the factors driving this impressive financial turnaround.